A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
Clinical trial NCT05681715 · COMPLETED
Trial details
- NCT number
- NCT05681715
- Sponsor
- UCB Biopharma SRL
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-17
- Primary completion
- 2024-04-23
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.